OBJECTIVE: The purpose of this research was to provide an initial examination of the effects of atomoxetine and stimulants on emotional expression using a newly developed scale for assessing emotional expression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: The parent-rated Expression and Emotion Scale for Children (EESC) was collected during two studies. During a cross-sectional validation study, the EESC was completed to assess the child's current treatment and retrospectively for previous medication. In a randomized, placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint. RESULTS: In the validation study, no statistically significant differences in EESC scores were found between groups taking atomoxetine (n = 74) and stimulants (n = 105). Patients who switched from a stimulant to atomoxetine (n = 40) had greater improvement in emotional expression than those switched to another stimulant (n = 21) (p = 0.008). In the clinical trial, no difference in rates of worsening of emotional expression were observed (atomoxetine 8.8%, placebo 12.3%; p = 0.440). CONCLUSION: No treatment differences in emotional expression were observed based on current medications. However, stimulant patients needing to switch medications may have greater improvements in emotional expression by switching to atomoxetine.
RCT Entities:
OBJECTIVE: The purpose of this research was to provide an initial examination of the effects of atomoxetine and stimulants on emotional expression using a newly developed scale for assessing emotional expression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: The parent-rated Expression and Emotion Scale for Children (EESC) was collected during two studies. During a cross-sectional validation study, the EESC was completed to assess the child's current treatment and retrospectively for previous medication. In a randomized, placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint. RESULTS: In the validation study, no statistically significant differences in EESC scores were found between groups taking atomoxetine (n = 74) and stimulants (n = 105). Patients who switched from a stimulant to atomoxetine (n = 40) had greater improvement in emotional expression than those switched to another stimulant (n = 21) (p = 0.008). In the clinical trial, no difference in rates of worsening of emotional expression were observed (atomoxetine 8.8%, placebo 12.3%; p = 0.440). CONCLUSION: No treatment differences in emotional expression were observed based on current medications. However, stimulant patients needing to switch medications may have greater improvements in emotional expression by switching to atomoxetine.
Authors: Atilla Turgay; Lawrence Ginsberg; Elias Sarkis; Rakesh Jain; Ben Adeyi; Joseph Gao; Bryan Dirks; Thomas Babcock; Brian Scheckner; Cynthia Richards; Robert Lasser; Robert L Findling Journal: J Child Adolesc Psychopharmacol Date: 2010-12 Impact factor: 2.576
Authors: Jonathan Posner; Tiago V Maia; Damien Fair; Bradley S Peterson; Edmund J Sonuga-Barke; Bonnie J Nagel Journal: Psychiatry Res Date: 2011-07-22 Impact factor: 3.222
Authors: Peter M Wehmeier; Ralf W Dittmann; Alexander Schacht; Karin Helsberg; Gerd Lehmkuhl Journal: Child Adolesc Psychiatry Ment Health Date: 2009-02-09 Impact factor: 3.033
Authors: Peter M Wehmeier; Alexander Schacht; Martin Lehmann; Ralf W Dittmann; Susan G Silva; John S March Journal: Child Adolesc Psychiatry Ment Health Date: 2008-05-28 Impact factor: 3.033
Authors: Rakesh Jain; Thomas Babcock; Teodor Burtea; Bryan Dirks; Ben Adeyi; Brian Scheckner; Robert Lasser; John Renna; Don Duncan Journal: Adv Ther Date: 2013-05-17 Impact factor: 3.845